BSX Boston Scientific | $46.75 +1.6% | 7/30/2026 | | Set Price Target | $60.00 | | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026 |
HUM Humana | $364.54 -0.6% | 7/30/2026 | | Upgrade | $513.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026 |
GOSS Gossamer Bio | $0.17 -4.9% | 7/28/2026 | | Upgrade | $1.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026 |
EW Edwards Lifesciences | $86.17 -0.9% | 7/24/2026 | | Upgrade | $87.00 ➝ $101.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026 |
MEDP Medpace | $577.11 -0.2% | 7/23/2026 | | Set Price Target | $620.00 | | 00.00% | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026 |
PGNY Progyny | $31.13 -1.1% | 7/22/2026 | | Set Price Target | $38.00 | | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026 |
GILD Gilead Sciences | $130.21 -0.8% | 7/21/2026 | | Downgrade | $146.00 ➝ $127.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026 |
STTK Shattuck Labs | $7.07 -1.7% | 7/20/2026 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026 |
ELV Elevance Health | $375.44 -0.3% | 7/17/2026 | | Boost Price Target | $364.00 ➝ $395.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026 |
ILMN Illumina | $205.10 +0.0% | 7/17/2026 | | Boost Price Target | $175.00 ➝ $210.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
TXG 10x Genomics | $47.27 -4.4% | 7/17/2026 | | Boost Price Target | $23.00 ➝ $40.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026 |
ISRG Intuitive Surgical | $353.33 +0.1% | 7/17/2026 | | Lower Price Target | $573.00 ➝ $454.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026 |
TWST Twist Bioscience | $91.55 +0.2% | 7/16/2026 | | Set Price Target | $110.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026 |
KARD Kardigan | $20.74 +1.3% | 7/13/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026 |
NGEN NervGen Pharma | $1.62 +1.3% | 7/13/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026 |
WHWK Whitehawk Therapeutics | $3.85
| 7/13/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026 |
BRKR Bruker | $62.84 -2.3% | 7/7/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026 |
AVTX Avalo Therapeutics | $18.25 -5.9% | 7/6/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026 |
PBLS Parabilis Medicines | $33.98 +5.3% | 7/6/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
PYXS Pyxis Oncology | $2.65 -7.7% | 7/2/2026 | | Lower Price Target | $9.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026 |
MLTX MoonLake Immunotherapeutics | $18.44 -2.9% | 7/1/2026 | | Boost Price Target | $24.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026 |
ABVX Abivax | $124.92 +0.5% | 6/30/2026 | | Boost Price Target | $140.00 ➝ $148.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026 |
TECH Bio-Techne | $72.09 +0.1% | 6/25/2026 | | Set Price Target | $73.00 | | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
LLY Eli Lilly and Company | $1,149.28 -0.5% | 6/25/2026 | | Boost Price Target | $1,119.00 ➝ $1,232.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026 |
IONS Ionis Pharmaceuticals | $51.77 -2.8% | 6/25/2026 | | Boost Price Target | $122.00 ➝ $129.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026 |
SPRY ARS Pharmaceuticals | $5.13 -8.9% | 6/25/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026 |
TECH Bio-Techne | $72.09 +0.1% | 6/25/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
QNCX Quince Therapeutics | $23.39 +1.6% | 6/24/2026 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026 |
RAPP Rapport Therapeutics | $40.98 -4.2% | 6/24/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026 |
RGNX REGENXBIO | $9.69 -4.2% | 6/22/2026 | | Boost Price Target | $17.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026 |
DFTX Definium Therapeutics | $43.52 -2.2% | 6/22/2026 | | Set Price Target | $30.00 ➝ $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026 |
ALT Altimmune | $2.84 -4.7% | 6/22/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026 |
QURE uniQure | $43.63 +3.4% | 6/18/2026 | | Boost Price Target | $36.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026 |
ARWR Arrowhead Pharmaceuticals | $84.65 -3.1% | 6/17/2026 | | Boost Price Target | $61.00 ➝ $72.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026 |
IONS Ionis Pharmaceuticals | $51.77 -2.8% | 6/17/2026 | | Boost Price Target | $114.00 ➝ $122.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026 |
UNH UnitedHealth Group | $414.82 -1.6% | 6/17/2026 | | Boost Price Target | $400.00 ➝ $462.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026 |
EWTX Edgewise Therapeutics | $38.43 -6.5% | 6/16/2026 | | Set Price Target | $52.00 | | 00.00% | View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026 |
SABS SAB Biotherapeutics | $3.57 +0.3% | 6/15/2026 | | Boost Price Target | $7.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026 |
PRCT PROCEPT BioRobotics | $18.62 +3.4% | 6/11/2026 | | Downgrade | $31.00 ➝ $29.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026 |
TNGX Tango Therapeutics | $27.18 -1.4% | 6/8/2026 | | Boost Price Target | $55.00 ➝ $69.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026 |
The end may be near for these iconic stocks (Ad) Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
SYK Stryker | $326.41 -6.2% | 6/5/2026 | | Lower Price Target | $410.00 ➝ $407.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026 |
NBTX Nanobiotix | $38.38 -4.4% | 6/4/2026 | | Boost Price Target | $37.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026 |
ABSI Absci | $7.78 +1.8% | 6/4/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026 |
MDT Medtronic | $85.64 -0.1% | 6/4/2026 | | Lower Price Target | $117.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026 |
NUVL Nuvalent | $123.96
| 6/3/2026 | | Set Price Target | $165.00 | | 00.00% | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/3/2026 |
VIR Vir Biotechnology | $8.66 -2.7% | 6/3/2026 | | Boost Price Target | $20.00 ➝ $21.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026 |
CELC Celcuity | $86.38 -1.4% | 6/2/2026 | | Set Price Target | $155.00 | | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026 |
FULC Fulcrum Therapeutics | $3.58 -3.8% | 6/2/2026 | | Downgrade | $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026 |
XFOR X4 Pharmaceuticals | $3.98 -0.5% | 6/2/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026 |
ICLR Icon | $163.30 -1.3% | 5/28/2026 | | Set Price Target | $145.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026 |
BSX Boston Scientific | $46.75 +1.6% | 5/28/2026 | | Lower Price Target | $87.00 ➝ $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026 |
EQ Equillium | $2.20 -5.2% | 5/28/2026 | | Upgrade | $1.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026 |
LLY Eli Lilly and Company | $1,149.28 -0.5% | 5/26/2026 | | Set Price Target | $1,119.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026 |
SPTX Seaport Therapeutics | $20.46 +0.7% | 5/26/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026 |
TWST Twist Bioscience | $91.55 +0.2% | 5/22/2026 | | Set Price Target | $80.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026 |
EHC Encompass Health | $111.27 +0.3% | 5/22/2026 | | Set Price Target | $152.00 | | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026 |
ROIV Roivant Sciences | $33.91 -1.8% | 5/21/2026 | | Set Price Target | $42.00 | | 00.00% | View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026 |
CGEN Compugen | $2.35 +0.4% | 5/21/2026 | | Lower Price Target | $13.00 ➝ $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026 |
IRD Opus Genetics | $3.71 -3.4% | 5/21/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026 |
REGN Regeneron Pharmaceuticals | $762.63 +3.3% | 5/18/2026 | | Reiterated Rating | $792.00 ➝ $641.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026 |
ONC BeOne Medicines | $316.01 -1.9% | 5/15/2026 | | Boost Price Target | $364.00 ➝ $367.00 | Outperform | 00.00% | View details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026 |
ANAB AnaptysBio | $53.36 -3.1% | 5/15/2026 | | Set Price Target | $90.00 | | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026 |
IMNM Immunome | $22.76 -1.4% | 5/15/2026 | | Lower Price Target | $37.00 ➝ $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026 |
STRO Sutro Biopharma | $24.17 -2.6% | 5/15/2026 | | Set Price Target | $38.00 ➝ $43.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026 |
RNA Avidity Biosciences | $11.35 -1.0% | 5/15/2026 | | Initiated Coverage | | Outperform | 00.00% | View details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026 |
DOCS Doximity | $20.95 -1.4% | 5/14/2026 | | Lower Price Target | $31.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026 |
AIRS AirSculpt Technologies | $4.81 -0.8% | 5/14/2026 | | Set Price Target | $4.50 | | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026 |
ANTX Anthem | $5.35 +0.4% | 5/14/2026 | | Upgrade | $9.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026 |
TNGX Tango Therapeutics | $27.18 -1.4% | 5/14/2026 | | Boost Price Target | $28.00 ➝ $55.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026 |
JNJ Johnson & Johnson | $256.52 +0.3% | 5/13/2026 | | Upgrade | $265.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026 |
AURA Aura Biosciences | $7.01 -1.4% | 5/12/2026 | | Set Price Target | $17.00 | | 00.00% | View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026 |
ALMR Alamar Biosciences | $25.36 +1.2% | 5/12/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026 |
KLRA Kailera Therapeutics | $16.94 -0.6% | 5/12/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026 |
ENGN enGene | $1.79 +1.7% | 5/8/2026 | | Downgrade | $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026 |
GILD Gilead Sciences | $130.21 -0.8% | 5/8/2026 | | Lower Price Target | $148.00 ➝ $146.00 | | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026 |
PODD Insulet | $165.35 -0.2% | 5/7/2026 | | Lower Price Target | $360.00 ➝ $247.00 | | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026 |
TWST Twist Bioscience | $91.55 +0.2% | 5/5/2026 | | Upgrade | $70.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026 |
ICLR Icon | $163.30 -1.3% | 5/4/2026 | | Set Price Target | $125.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026 |
ORKA Oruka Therapeutics | $96.64 -1.2% | 4/30/2026 | | Set Price Target | $120.00 | | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026 |
ALGN Align Technology | $169.16 -2.5% | 4/30/2026 | | Boost Price Target | $225.00 ➝ $230.00 | | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026 |
HUM Humana | $364.54 -0.6% | 4/30/2026 | | Boost Price Target | $185.00 ➝ $255.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026 |
NEO NeoGenomics | $15.29 -3.7% | 4/29/2026 | | Upgrade | $12.00 ➝ $25.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026 |
ANAB AnaptysBio | $53.36 -3.1% | 4/28/2026 | | Boost Price Target | $66.00 ➝ $85.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/28/2026 |
CRMD CorMedix | $7.53 +0.5% | 4/28/2026 | | Boost Price Target | $13.00 ➝ $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 4/28/2026 |
NTLA Intellia Therapeutics | $10.68 -3.7% | 4/27/2026 | | Set Price Target | $35.00 | | 00.00% | View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026 |
HCA HCA Healthcare | $403.44 +1.9% | 4/27/2026 | | Lower Price Target | $573.00 ➝ $500.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 4/27/2026 |
LLY Eli Lilly and Company | $1,149.28 -0.5% | 4/27/2026 | | Lower Price Target | $1,296.00 ➝ $1,058.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 4/27/2026 |
TRAX First Tracks Biotherapeutics | $44.04 -7.8% | 4/24/2026 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 4/24/2026 |
ELV Elevance Health | $375.44 -0.3% | 4/23/2026 | | Set Price Target | $364.00 | | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 4/23/2026 |
BBNX Beta Bionics | $12.83 -10.1% | 4/22/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 4/22/2026 |
Porter flew 3,300 miles to investigate this system (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself |
DFTX Definium Therapeutics | $43.52 -2.2% | 4/22/2026 | | Boost Price Target | $23.00 ➝ $30.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 4/22/2026 |
DNLI Denali Therapeutics | $23.02 -5.5% | 4/22/2026 | | Lower Price Target | $40.00 ➝ $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Denali Therapeutics (NASDAQ:DNLI) on 4/22/2026 |
ISRG Intuitive Surgical | $353.33 +0.1% | 4/22/2026 | | Lower Price Target | $622.00 ➝ $573.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 4/22/2026 |
JAZZ Jazz Pharmaceuticals | $252.86 -2.1% | 4/22/2026 | | Boost Price Target | $215.00 ➝ $225.00 | Outperform | 00.00% | View details for Leerink Partners rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 4/22/2026 |
MANE Veradermics | $105.05 +0.4% | 4/22/2026 | | Boost Price Target | $75.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of Veradermics (NYSE:MANE) on 4/22/2026 |
NBIX Neurocrine Biosciences | $166.80 -10.1% | 4/22/2026 | | Boost Price Target | $160.00 ➝ $170.00 | Outperform | 00.00% | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 4/22/2026 |
UNH UnitedHealth Group | $414.82 -1.6% | 4/22/2026 | | Boost Price Target | $345.00 ➝ $400.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 4/22/2026 |
ABT Abbott Laboratories | $105.99 +0.4% | 4/21/2026 | | Lower Price Target | $119.00 ➝ $106.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 4/21/2026 |
RCUS Arcus Biosciences | $28.18 -0.3% | 4/20/2026 | | Set Price Target | $47.00 | | 00.00% | View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 4/20/2026 |
FTH Sensei Biotherapeutics | $27.24 -5.5% | 4/20/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sensei Biotherapeutics (NASDAQ:FTH) on 4/20/2026 |